• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pfizer Inc.

Pfizer agrees to pay $345M in EpiPen pricing lawsuit

July 16, 2021 By Sean Whooley

legal

Pfizer (NYSE:PFE) agreed to pay $345 million to settle claims of overpayments for EpiPens due to alleged anti-competitive and unfair practices. Reuters reported that a filing disclosed in federal court in Kansas City, Kan., revealed the settlement set to resolve claims from consumers who say they overpaid for EpiPens with the alleged anti-competitive and unfair practices […]

Filed Under: Auto-injectors, Business/Financial News, Drug-Device Combinations, Featured, Legal News, Pharmaceuticals Tagged With: epipen, Mylan, Pfizer Inc., Viatris

Pharma 50: Here’s how the world’s largest pharma companies are doing

May 12, 2021 By Chris Newmarker

Pharma 50 50 largest pharma companies pharmaceutical

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data […]

Filed Under: Featured, Pharmaceuticals Tagged With: AstraZeneca plc, Gilead Sciences, GlaxoSmithKline plc, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer Inc., Pharma 50, Roche, sanofi, Sinopharm

Pfizer to absorb Mylan in off-patent drug spinout

July 29, 2019 By Brad Perriello

Pfizer to merge Upjohn with Mylan

Pfizer (NYSE:PFE) plans to absorb Mylan (NSDQ:MYL) as part of the spinout of its Upjohn off-patent drugs business in an all-stock deal. The deal, structured to avoid taxes on any gains from the spinout, would see each Mylan share converted into a share of the as-yet-unnamed new company. Pfizer stockholders would then own 57% of […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beat Tagged With: Mylan, Pfizer Inc.

Teva launches generic for Pfizer’s Flector pain patch

March 4, 2019 By Sarah Faulkner

Teva Pharmaceuticals - updated logo

Teva (NYSE:TEVA) said last week that it launched a generic version of Pfizer‘s (NYSE:PFE) Flector diclofenac epolamine patch. Using a nonsteroidal anti-inflammatory drug, the topical patch is designed to treat acute pain due to minor strains, sprains and contusions. Pfizer’s Flector patch garnered annual sales of $123 million in the U.S. as of Dec. 2018, according […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pain Management, Pharmaceuticals, Wall Street Beat Tagged With: Pfizer Inc., Teva Pharmaceuticals

Report: Pharma companies kick off new year with price hikes

January 2, 2019 By Sarah Faulkner

Prescription drugs

Major pharmaceutical firms started the new year by hiking the prices of hundreds of drugs, according to a new study published by Rx Savings Solutions. First reported in The Wall Street Journal, the study found that the average price increase taken by more than three dozen companies was roughly 6.3%. Allergan (NYSE:AGN) topped the list, raising the […]

Filed Under: Business/Financial News, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Biogen, Bristol-Myers Squibb Co., Eli Lilly & Co., Pfizer Inc.

FDA warns of flesh-eating genital infection linked to diabetes drug

August 31, 2018 By Fink Densford

FDA

The FDA this week warned of serious flesh-eating bacterial infections, or necrotizing fasciitis, reported by patients taking sodium-glucose cotransporter-2 (SGLT2) inhibitors intended for treating type 2 diabetes. The federal watchdog said that between March 2013 and May 2018, 12 cases of Fournier’s gangrene, a rare but life-threatening bacterial infection of the tissue under the skin […]

Filed Under: Diabetes, Featured, Food & Drug Administration (FDA), Pharmaceuticals Tagged With: AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly & Co., johnsonandjohnson, Merck, Pfizer Inc.

Sage Therapeutics’ chief scientist on discovering drugs and taking risks

June 29, 2018 By Sarah Faulkner

Sage Therapeutics

When Al Robichaud got his start as a medicinal chemist in 1991, he knew that discovering and developing drugs meant shouldering some level of risk. But around 2011, it became clear that the process for developing brain drugs was too costly and risky for major pharmaceutical companies to justify pursuing, as companies including Novartis (NYSE:NVS), GlaxoSmithKline (NYSE:GSK), […]

Filed Under: Discovery, Drug-Device Combinations, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: GlaxoSmithKline plc, Novartis, Pfizer Inc., sagetherapeutics, Sanofi-Aventis

Hospira issues nationwide recall for opioid overdose reversal drug

June 6, 2018 By Sarah Faulkner

Pfizer

Pfizer‘s (NYSE:PFE) Hospira unit this week voluntarily recalled two lots of a drug used to reverse the course of an opioid overdose. The company’s naloxone injection, sold in its Carpuject single-use cartridge syringe, was recalled due to the potential presence of embedded and loose particulate matter in the plunger. Hospira specifically warned that products from lots 72680LL and 76510LL […]

Filed Under: Auto-injectors, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Recalls, Wall Street Beat Tagged With: Hospira Inc., Pfizer Inc.

Report: Pharma companies ask Supremes to take eye-dropper case

April 2, 2018 By Sarah Faulkner

gavel

A group of pharmaceutical companies, including Allergan (NYSE:AGN) and Merck (NYSE:MRK), have asked the Supreme Court to review a case between the industry players and patients regarding the design of the companies’ eye-droppers, according to a report from the AP. In the on-going legal debate, patient groups have claimed that the companies’ devices dispense large drops of medication […]

Filed Under: Drug-Device Combinations, Featured, Legal News, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Merck, Pfizer Inc.

Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies

January 30, 2018 By Sarah Faulkner

National Institutes of Health logo

The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the […]

Filed Under: Clinical Trials, Featured, Neurological, Pharmaceuticals, Wall Street Beat Tagged With: Celgene, GlaxoSmithKline plc, michaeljfoxfoundation, National Institutes of Health, Pfizer Inc., Sanofi-Aventis, Verily

  • Page 1
  • Page 2
  • Page 3
  • Interim pages omitted …
  • Page 5
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS